Pfizer sells, but keeps Sweden HQ; 6 hospitalized after leak at Novartis plant

@FiercePharma: Sanofi, Merck, others said to be eyeing Bausch buyout. Story | Follow @FiercePharma

> Six people were hospitalized Tuesday after a leak at a Novartis ($NVS) drug plant near Basel. Story 

> Pfizer ($PFE) is raising about $27.7 million in a deal to sell and lease back its Swedish headquarters in Stockholm. Item 

> Pfizer has agreed to pay $55 million to resolve charges of marketing violations against Wyeth for the acid reflux drug Protonix. Story

> India drug exports grew by more than 23% in the last fiscal year. Item

> The EU has voted to put patents on sale, cutting costs by about 80%. Story 

Medical Device News

 @FierceMedDev: Medtronic facing federal suit from 'exploited' patients. Story | Follow @FierceMedDev

@MarkHFierce: Cerapedics pulled in a $19M Series C for its bone graft development work. New investors include MedImmune. More | Follow @MarkHFierce

 @DamianFierce: Welch Allyn isn't done reorganizing. After announcing plans to cut 275 jobs, it's moving its Euro HQ. Article | Follow @DamianFierce

> Myriad, Sanofi to team on diabetes biomarker Dx discovery work. Item

> BG Medicine gains CE mark for cardiovascular Dx. News

Biotech News

 @FierceBiotech: Nuron acquires Pfizer's meningitis vaccine. Story | Follow @FierceBiotech

@JohnCFierce: What does Lilly have? A signal, unconfirmed, that solanezumab works in mild Alzheimer's. See you in 3-4 years, alongside much competition. | Follow @JohnCFierce

@RyanFierce: $GILD wants a piece of the big oncology pie, as it showed with the Yale deal last year. YM could get it there sooner. Report | Follow @RyanMFierce

> GlaxoSmithKline backs upstart's $17M A round for therapy against bulging-eye ailment. Article

> Eli Lilly ditches FDA filing for Alzheimer's hope solanezumab. News

Drug Delivery News

> Eleven's lead topical eye drug completes PhIa, enters PhIb trials. Report

> Silver bullet targets antibiotics to deep infections. News

> Porcupine quills point to less painful shots. Story

> Sirtex, SingHealth develop stealth cancer treatments. Article

> Alnylam plans clinical trials for RNAi therapeutic. More

And Finally... Records from the U.S. House show that Ranbaxy Laboratories, the Indian generics maker that last year signed a 5-year consent decree with U.S. authorities, paid $90,000 to a lobbying firm. Ranbaxy has paid $90,000 to lobbyists Patton Boggs to work such angles as preserving "Access to Affordable Generics," according to a document registered in 2010. Story


Suggested Articles

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.